The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterizing patterns of disease progression in patients with genitourinary cancers treated with immune checkpoint inhibitors.
 
Vaibhav G. Patel
No Relationships to Disclose
 
Qian Qin
No Relationships to Disclose
 
George Mellgard
No Relationships to Disclose
 
Anish B. Parikh
No Relationships to Disclose
 
Bo Wang
No Relationships to Disclose
 
Parissa Alerasool
No Relationships to Disclose
 
Philip Garcia
No Relationships to Disclose
 
Suraj Jaladanki
No Relationships to Disclose
 
Amanda Leiter
No Relationships to Disclose
 
Emily Carroll
No Relationships to Disclose
 
Danielle Brooks
No Relationships to Disclose
 
Jennifer Ben Shimol
No Relationships to Disclose
 
Elliot Eisenberg
No Relationships to Disclose
 
Emily J. Gallagher
No Relationships to Disclose
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
William K. Oh
Leadership - checkpoint Sciences
Stock and Other Ownership Interests - Bellicum Pharmaceuticals
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; checkpoint Sciences; HUYA Bioscience International; Janssen; Sanofi; Sema4; TeneoBio; TYME
Research Funding - Constellation Pharmaceuticals; Sotio (Inst)
 
Che-Kai Tsao
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Pfizer